Overview

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

Status:
Completed
Trial end date:
2006-02-13
Target enrollment:
Participant gender:
Summary
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Sitagliptin Phosphate